Skip to main content

Table 1 Results from the all outcomes trials with the major fibrates (gemfibrozil, bezafibrate, fenofibrate)

From: Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Study Primary analysis: RRR (p value) Subgroup criteria Subgroup analysis:
(Treatment) RRR (p value)
HHS[32, 43] −34% (<0.02) TG >200 mg/dL −71% (0.005)
(Gemfibrozil) LDL-C/HDL-C >5.0
VA-HIT[44] −22% (0.006) Diabetes −34% (0.004)
(Gemfibrozil)
BIP[42] −9.4% (0.24) TG >200 mg/dL, −42% (0.02)
(Bezafibrate) HDL-C < 35 mg/dL,
FIELD[41, 45] −11% (0.16) TG ≥200 mg/dL −27% (0.005)
(Fenofibrate) HDL-C <40 mg/dL for men, <50 mg/dL for women
ACCORD Lipid[39] −8% (0.32) TG ≥204 mg/dL −31% (0.03)
(Fenofibrate) HDL-C ≤34 mg/dL
  1. RRR – relative risk reduction.